Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Batten Disease
StemCells, Inc. Announces Important Milestone in Batten Disease Clinical Trial
July 6th, 2007
StemCells, Inc. (NASDAQ: STEM) announced that the Phase I clinical trial of its proprietary HuCNS-SC(TM) product candidate (purified human neural stem cells) has successfully completed enrollment of the low-dose cohort and will proceed to the high-dose cohort. This trial is designed to evaluate the safety and preliminary efficacy of the HuCNS-SC product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease. To date, three patients out of a planned total of six have been transplanted with HuCNS-SC cells. A review of the trial data to date, conducted by an independent Data Safety Monitoring Committee comprised...
Source: Genomics & Genetics Weekly (2007-07-06)
|
